Thrivent Financial for Lutherans’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
VCM
DM
VPM
Thrivent Financial for Lutherans's CPRX Position: Q1 2026 in Review
Thrivent Financial for Lutherans reduced its Catalyst Pharmaceutical (CPRX) stake by 2.9% in Q1 2026, selling an estimated $54.1K and leaving 77,119 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1498.
Thrivent Financial for Lutherans first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $2M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Thrivent Financial for Lutherans held 77,119 shares of Catalyst Pharmaceutical worth $1.91M as of Q1 2026.
- Thrivent Financial for Lutherans sold 2,270 Catalyst Pharmaceutical shares in Q1 2026, an estimated $54.1K.
- Catalyst Pharmaceutical made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1498 holding.
- Thrivent Financial for Lutherans first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
- Thrivent Financial for Lutherans's Catalyst Pharmaceutical position peaked at $2M in Q1 2025.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.